ABIOMED, Inc. Announces New Data Confirms Early Implantation Of Impella 2.5 Prior To PCI Improves Survival In Shock Patients

ABIOMED, Inc. announced new results from a multicenter retrospective study demonstrating that early initiation of support with Impella 2.5 prior to revascularization improves survival in emergent patients as compared to those receiving Impella 2.5 support after percutaneous coronary intervention (PCI). Specifically, the analysis demonstrated that shock patients that received Impella before revascularization had a higher survival rate (65% vs. 39%, p=0.007 respectively, N=119). The results of the study were presented today by William O’Neill, M.D. of the University of Miami, at the annual 2011 Transcatheter Cardiovascular Therapeutics (TCT) meeting and included 119 patients receiving emergent PCI with Impella at 32 U.S. centers. The data from this analysis supports the recently released new ACCF/AHA/SCAI guidelines which included Impella as a Class I recommendation for cardiogenic shock after STEMI.